A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.

Autor: Tian XP; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Xie D; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Huang WJ; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, PR China., Ma SY; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Wang L; Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, PR China.; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China., Liu YH; Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, PR China., Zhang X; Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, PR China., Huang HQ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Lin TY; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Rao HL; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Li M; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Liu F; Department of Pathology, The First People's Hospital of Foshan, Foshan, PR China., Zhang F; Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, PR China., Zhong LY; Department of Hematology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, PR China., Liang L; Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, PR China., Lan XL; Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, PR China., Li J; Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China., Liao B; Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China., Li ZH; Department of Oncology, Sun-Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China., Tang QL; Department of Oncology, Sun-Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China., Liang Q; Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China., Shao CK; Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China., Zhai QL; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China., Cheng RF; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China., Sun Q; Department of Pathology, Hematological Hospital of Chinese Academy of Medical Sciences, Tianjin, PR China., Ru K; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China., Gu X; Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, PR China., Lin XN; Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, PR China., Yi K; Department of Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, PR China., Shuang YR; Department of Hematology, Jiangxi Provincial Cancer Hospital, Nanchang, PR China., Chen XD; Department of Pathology, General Hospital of Guangzhou Military Command of PLA, Guangzhou, PR China., Dong W; Department of Hematology, Shunde Hospital of Southern Medical University, Shunde, PR China., Sang W; Department of Hematology, The First Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China., Sun C; Department of Pathology, The First Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China., Liu H; Department of Pathology, The First Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China., Zhu ZG; Department of Hematology and Oncology, Guangzhou First People's Hospital, Guangzhou, PR China., Rao J; Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, PR China., Guo QN; Department of Pathology, Xinqiao Hospital, Third Military Medical University, Chongqing, PR China., Zhou Y; Department of Medical Oncology, Jiangmen Central Hospital, Jiangmen, PR China., Meng XL; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, PR China., Zhu Y; Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, PR China., Hu CL; Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, PR China., Jiang YR; Department of Hematology, The First People's Hospital of Dongguan, Dongguan, PR China., Zhang Y; Department of Oncology, Affiliated Hospital of Guangdong Medical University, Guangzhou, PR China., Gao HY; Department of Pathology, Guangdong Province Hospital for Women and Children Health Care, Guangzhou, PR China., He WJ; Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, PR China., Xia ZJ; Department of Hematology, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Pan XY; Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, PR China., Lan H; Department of Hematology, Shunde Affiliated Hospital of Guangzhou University of Chinese Medicine, Shunde, PR China., Li GW; Department of Hematology, Huizhou Municipal Central Hospital, Huizhou, PR China., Liu L; Department of Lymphoma And Hematology, Jilin Cancer Hospital, Changchun, PR China., Bao HZ; Department of Lymphoma And Hematology, Jilin Cancer Hospital, Changchun, PR China., Song LY; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, PR China., Kang TB; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Cai QQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China. caiqq@sysucc.org.cn.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China. caiqq@sysucc.org.cn.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2020 Sep; Vol. 34 (9), pp. 2392-2404. Date of Electronic Publication: 2020 Feb 20.
DOI: 10.1038/s41375-020-0757-5
Abstrakt: We aimed to establish a discriminative gene-expression-based classifier to predict survival outcomes of T-cell lymphoblastic lymphoma (T-LBL) patients. After exploring global gene-expression profiles of progressive (n = 22) vs. progression-free (n = 28) T-LBL patients, 43 differentially expressed mRNAs were identified. Then an eleven-gene-based classifier was established using LASSO Cox regression based on NanoString quantification. In the training cohort (n = 169), high-risk patients stratified using the classifier had significantly lower progression-free survival (PFS: hazards ratio 4.123, 95% CI 2.565-6.628; p < 0.001), disease-free survival (DFS: HR 3.148, 95% CI 1.857-5.339; p < 0.001), and overall survival (OS: HR 3.790, 95% CI 2.237-6.423; p < 0.001) compared with low-risk patients. The prognostic accuracy of the classifier was validated in the internal testing (n = 84) and independent validation cohorts (n = 360). A prognostic nomogram consisting of five independent variables including the classifier, lactate dehydrogenase levels, ECOG-PS, central nervous system involvement, and NOTCH1/FBXW7 status showed significantly greater prognostic accuracy than each single variable alone. The addition of a five-miRNA-based signature further enhanced the accuracy of this nomogram. Furthermore, patients with a nomogram score ≥154.2 significantly benefited from the BFM protocol. In conclusion, our nomogram comprising the 11-gene-based classifier may make contributions to individual prognosis prediction and treatment decision-making.
Databáze: MEDLINE